Analytical Data
-
Gene name
B7-2/CD86
-
简介
B7-2/CD86 protein negatively regulates T-cell activation by disrupting CD86 cluster formation, modulating the T-cell response, and influencing immune activation. B7-2/CD86 Protein, Human (Biotinylated, HEK293, hFc, Avi) is the recombinant human-derived B7-2/CD86 protein, expressed by HEK293, with Avi and C-hFc labeled tag.
- Application
-
Alternative Names
CD86 molecule; CD86; B70; B7-2 antigen; B72; B7-2; BU63; FUN-1; LAB72; MGC34413; CD28LG2
-
Species
Human
-
Source
HEK293
-
Tag
Avi;C-hFc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P42081-3
-
Expression Region
K21-H239
-
Protein Length
Partial
-
Molecular Weight
92 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
B7-2, also known as CD86, is a crucial co-stimulatory molecule involved in the regulation of immune responses, primarily participating in T-cell activation. It is primarily expressed on antigen-presenting cells (APCs) such as dendritic cells, macrophages, and B cells. The interaction of B7-2/CD86 with its receptor CD28 on T cells provides essential signals for T-cell activation and survival, thereby playing a key role in the adaptive immune response. Research into B7-2/CD86 has gained significant interest due to its implications in various immunological disorders, including autoimmune diseases, cancer, and transplant rejection. In cancer immunotherapy, B7-2/CD86 is being explored as a potential target for enhancing anti-tumor responses, as its expression can influence the efficacy of immune checkpoint inhibitors. Moreover, recombinant B7-2/CD86 proteins are being developed to understand their structural and functional properties, which could lead to novel therapeutic strategies aimed at modulating immune responses. By elucidating the molecular mechanisms of B7-2/CD86 interactions with T cells, researchers aim to design innovative approaches to either stimulate or suppress immune responses in a controlled manner, paving the way for advancements in vaccination strategies and immunotherapy applications. Thus, the study of B7-2/CD86 recombinant proteins not only enhances our understanding of immune regulation but also holds promise for developing new therapeutic modalities to treat various diseases where the immune system plays a pivotal role.
